

I hereby certify that this correspondence is being electronically transmitted via EFS-Web to the United States Patent and Trademark Office, Mail Stop: Amendment on this 21st day of February 2007.

s/Julie Agozino/
Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
LYN HOWARD JONES, et al

Group Art Unit: 1614

Serial No.: **10/599,707**

Examiner: Not Yet Assigned

Confirmation No.: **3037**

Filed: **October 5, 2006**

For: **SULFER-LINKED IMIDAZOLE
COMPOUNDS FOR THE TREATMENT OF
HIV**

Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97

37 CFR § 1.97(b)

The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 16-1445.

Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date	Docket No.
10/657,033	09-05-2003	PC25402A

Copies of these copending applications are enclosed.

Applicant hereby requests consideration of the Information Disclosure Statement, PTO/SB/08, submitted herewith. Copies of the cited references, except as noted below, are enclosed.

This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.

Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (waiver of 37 CFR 1.98(a)(2)(ii) pursuant to 37 CFR 1.183).

Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

Derwent Abstracts enclosed for foreign language applications WO 02/42279, O00/06569, WO 98/16507, WO 00/21954, WO 02/42300, WO 02/42302, WO 02/42301, DE 198 34 047 A, WO 00/06567, AND WO 8/23919.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 16-1445. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: February 21, 2007

/Jeffrey H. Tidwell/

Jeffrey H. Tidwell
Attorney for Applicants
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10555 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233